Mr. Deng, has amassed extensive experience in research, investment, and management across the healthcare sector. In November 2025, he joined CRM and was appointed as a director of CRM, where he was primarily responsible for participating in discussions on the group’s major decision-making matters and providing strategic opinions and suggestions on the group’s operation and management.

Currently serving at Yunfeng Capital (云锋基金), Mr. Deng leads and participates in investments and cross-border transactions across multiple sectors including biopharmaceuticals, cell therapies, medical devices and healthcare services. He has spearheaded or played a key role in the investment and post-investment management of nearly 20 portfolio companies to date.

Mr. Deng graduated from Peking University Health Science Center (北京大学医学部) with a bachelor’s degree in July 2020. In the same month, he obtained a dual bachelor’s degree in economics from the National School of Development at Peking University (北京大学国家发展研究院). He obtained a master’s degree in finance from Fudan University (复旦大学) in June 2022.